Editas medicine to present in vivo hsc delivery, editing, and biodistribution data at the european hematology association 2025 congress in june

Preclinical studies achieved therapeutically relevant gene editing levels of the hbg1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy data reinforces continued development as a potentially transformative, in vivo approach to treating sickle cell disease and beta thalassemia cambridge, mass., may 14, 2025 (globe newswire) -- editas medicine, inc. (nasdaq: edit), a pioneering gene editing company, today announced that new data from a study in non-human primates (nhps) has been accepted for a poster presentation at the european hematology association (eha) 2025 congress being held june 12-15, 2025, in milan, italy.
HSC Ratings Summary
HSC Quant Ranking